The achieved dose of spironolactone in the TOPCAT trial was similar to the mean dose in the Randomized Aldactone Evaluation Study,14 and dose adjustments were limited by elevations in serum creatinine and potassium levels. Approximately one third of participants discontinued the study drug for these and … Zobraziť viac Many patients with heart failure have a normal or near-normal left ventricular ejection fraction.1-4 Such patients share common signs … Zobraziť viac We designed a phase 3, multicenter, international, randomized, double-blind, placebo-controlled trial. The trial was sponsored by the National Heart, Lung, and Blood … Zobraziť viac Among patients with heart failure and a reduced ejection fraction and those with myocardial infarction complicated by heart failure and left … Zobraziť viac Patients 50 years of age or older were eligible if they provided written informed consent and had at least one sign and at least one symptom of heart failure on a prespecified list of clinically defined signs and symptoms, a … Zobraziť viac WebIn patients enrolled in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist) trial, those with abdominal obesity had higher event rates, including cardiovascular death. 3 In TOPCAT, spironolactone reduced the primary outcome of HF hospitalization or cardiovascular death in the reliable patient cohort ...

Spironolactone Metabolites in TOPCAT — New Insights into …

WebObjectives: This study investigated an enriched cohort of patients with heart failure and preserved ejection fraction (HFpEF) in TOPCAT (Treatment of Preserved Cardiac Function … WebConclusion: Spironolactone does not reduce the risk of new-onset AF or AF recurrence in patients with HFpEF. This is in contrast to results in cohorts of patients with HF and a … dental assistant job outlook chart by state

Balancing Benefits and Risks of Spironolactone in HFpEF and …

WebSpironolactone up-titration may be limited by side effects that could be minimized at lower than target doses, but whether lower than target doses remain efficacious is unknown. In … Web19. jún 2024 · The lack of an effect of spironolactone on the prevention of new-onset AF or AF recurrence in this study may be due to the neutral primary results concerning HF outcomes in the TOPCAT trial. Indeed, TOPCAT investigators stratified patients to AF or no AF at baseline and found no differential effect of spironolactone or placebo on the main … Web27. jan 2024 · Ferreira et al. conducted a post hoc analysis of spironolactone dose with patients from “TOPCAT-Americas” and suggested that for elderly HFpEF patients with high serum potassium levels and impaired renal function, < 25 mg (around 15 mg/day–20 mg/day) of spironolactone might be a better choice instead of stopping treatment … dental assistant in the military